The use of interferon drugs against COVID-19 is based on С level of evidence and analogies with efficacy against other coronaviruses. The interferon inductor meglumin acridonacetate (Cycloferon) has an advantageous safety profile and phar-maco-economic advantages, which makes it possible to consider its probable use against SARS-CoV-2. In this review, both the evidence of the effectiveness of interferons against coronaviruses and the arguments in favor of the effectiveness of Cycloferon against the same pathogens are systematized. The arguments of pharmacodynamic, biochemical, pathophysiological experimental and clinical plan in favor of Cycloferon are presented.